Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2020

View Archived Issues

How CDK comes unglued

HRAS-driven translation helps skin prevent tumors

Phase I study of BAY-1436032 in advanced AML patients with mutant IDH1

Preliminary phase I results suggest neihulizumab safety and efficacy in sr-aGvHD

Hyundai Pharmaceutical presents phase I data for GPR40 agonist HD-6277 in type 2 diabetes

Stayble Therapeutics initiates phase IIb study of STA-363

Positive data presented from FASCINATE-1 phase II study of ASC-40

Dare Bioscience initiates pivotal phase III study of DARE-BV1 in bacterial vaginosis

Encouraging interim data presented from phase II/III study of IFX-1 in severe COVID-19

Safety run-in results from phase I/II study of VXM-01 plus avelumab in progressive glioblastoma

First clinical results presented for PXS-5505

Otsuka Pharmaceutical presents new antiseizure compounds

New MALT1 inhibitors discovered at Takeda

Novartis describes new PCSK9 inhibitors

Merck & Co. patents IDO-1 inhibitors

GlaxoSmithKline and collaborators identify NF-kappaB activators/HIV latency-reversing agents

Xoc Pharmaceuticals presents phase I data for XC101-D13H in preventing migraine

Aevi begins phase II study of CERC-002 in patients with COVID-19 pneumonia and acute lung injury

Preclinical and phase I studies demonstrate KER-050 potential for treating hematopoiesis disorders

Sanofi begins phase III trials of SAR-442168 in MS

ViralClear enrolls patients with advanced COVID-19 in phase II trial of merimepodib with remdesivir

New phase I trial studies TQB-3474 in advanced malignant tumors

New targets and "molecular beacon" give new insights into senescence

Phase II trial explores axatilimab in patients with respiratory involvement secondary to COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...